Shionogi & Co., Ltd. is a research-driven pharmaceutical company headquartered in Osaka, Japan, with origins dating back to 1878. The company concentrates on the discovery, development and sale of prescription medicines in key therapeutic areas, including infectious diseases, pain management, cardiovascular and metabolic disorders, central nervous system disorders and oncology. Shionogi’s mission emphasizes addressing unmet medical needs, particularly in the field of antimicrobial resistance, where it has developed both small-molecule antibiotics and novel treatment approaches.
The firm’s product portfolio comprises marketed therapies such as Cresemba (isavuconazole) for invasive fungal infections, and Fetroja (cefiderocol), a siderophore cephalosporin antibiotic for multidrug-resistant Gram-negative infections. Shionogi also co-develops and licenses compounds in collaboration with global partners, leveraging alliances with leading pharmaceutical companies across North America, Europe and Asia. Its pipeline includes candidates targeting pain, metabolic disease and oncology indications, reflecting a balanced strategy of in-house research and strategic partnerships.
Shionogi conducts its research and development through facilities in Japan and overseas, with key affiliates and subsidiaries in the United States, the United Kingdom, China and Australia. The company’s international footprint is supported by manufacturing sites compliant with global regulatory standards. Governance is overseen by a board of directors and executive officers, who guide Shionogi’s long-term strategy focused on innovative drug discovery, sustainable business growth and contributions to public health worldwide.
AI Generated. May Contain Errors.
